2019 Biotechnology Market Consolidation: Who will not survive?

This report is part of the Competitive Analysis Series prepared to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation to the leading competitors.

The series includes current assessments of more than 1,000 companies worldwide. Depending on the company’s business nature and structure, the assessments include all or some of the following analyses: Organization and Management, Acquisitions and Divestitures, Facilities and Employees, Research and Development, Technological Know-How, Key Products, Marketing Capabilities, Financial Results, Strengths and Weaknesses, and Strategic Directions.

The Top10 report analyzes the following companies:

Actavis
Amgen
Biogen
Celgene
Gilead Sciences
Merck
Novo Nordisk
Roche
Shire
Teva

Individual company reports $950.

The report provides significant competitor information, analysis and insight critical to the development and implementation of effective marketing and R&D programs.

In the dynamic and fragmented Biotechnology industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.

The report’s objectives include:

- To assist potential market entrants in evaluating prospective acquisitions and joint venture candidates.
- To complement organizations’ internal competitor information gathering efforts with strategic analysis, data interpretation and insight.